No Early Effect of Intrathecal Rituximab in Progressive Multiple Sclerosis (EFFRITE Clinical Trial)

BACKGROUND: The progressive phase of multiple sclerosis (MS) is characterized by an intrathecal (IT) compartmentalization of inflammation, involving B-cells within meningeal follicles, and resisting all the available immunosuppressive treatments. A new therapeutic paradigm may be to target this infl...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Mult Scler Int
Autors principals: Bonnan, Mickael, Ferrari, Sylvie, Courtade, Henri, Money, Paul, Desblache, Pauline, Barroso, Bruno, Debeugny, Stéphane
Format: Artigo
Idioma:Inglês
Publicat: Hindawi 2021
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7964121/
https://ncbi.nlm.nih.gov/pubmed/33763241
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2021/8813498
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars